Dimerix (DXB) Stock Price, News & Analysis

Company Overview

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $282.11 million
• P/E Ratio: N/A
• Dividend Yield: 5.16%
• Price Target: N/A
• Consensus Rating: N/A

DXB Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Dimerix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dimerix investors own include Immuron (IMRN), Noxopharm (NOX), Tabcorp (TAH), NexGen Energy (NXE) and Kazia Therapeutics (KZIA).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:DXB
• CIK: N/A
• Web: dimerix.com
• Phone: 1.212.250.8024
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.08 million
• Net Margins: -2,926.43%
• Pretax Margin: N/A
• Return on Equity: -171.59%
• Return on Assets: -42.83%

Debt

• Debt-to-Equity Ratio: 0.82
• Current Ratio: 9.49
• Quick Ratio: 7.91

Sales & Book Value

• Annual Sales: $9.12 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.04 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 557,130,000
• Free Float: N/A
• Market Cap: $282.11 million
• Optionable: Not Optionable
• Beta: 0.53